Enzolytics Inc - ENZC stock
OTC Symbol: ENZC | OTC Tier: Pink Current
About[edit]
Enzolytics Inc (OTC: ENZC) is a biotechnology company focused on developing innovative therapies for infectious diseases, including HIV/AIDS. The company was founded in 2014 and is headquartered in Houston, Texas.[1]
Products[edit]
Treatment for HIV/AIDS[edit]
Enzolytics is focused on the development of a proprietary therapeutic protein called ITV-1, which has shown potential as a treatment for a variety of infectious diseases. ITV-1 is a recombinant protein derived from a natural human protein called CD4. The protein has been shown to bind to and inactivate viruses, including HIV, and may also stimulate the immune system's response to these viruses.[2] Enzolytics is conducting preclinical studies and clinical trials to evaluate the safety and efficacy of ITV-1 as a treatment for HIV/AIDS.
Nitric Oxide Compound[edit]
Enzolytics, Inc. has signed a Letter of Intent with Enogenesis (ENGN) for an exclusive licensing agreement for ENGN’s patented Nitric Oxide Compound (NOC). This partnership aims to integrate NOC into the nutraceutical products of Enzolytics’ subsidiary, Virogentics Inc. (VIRO), which currently offers immune support, brain and liver detox, and weight loss formulations. NOC can be incorporated in liquid, solid, or spray forms into VIRO’s existing product lines.[3]
Pepsin Fragments[edit]
Enzolytics, Inc. has entered into a worldwide exclusive licensing agreement for U.S. Patent #8067531-B2, titled "Inactivated Pepsin Fragments for Modulating Immune System Activity Against Human Malignant Tumor Cells." This patent applies immunotherapy treatment to cancer, reinforcing Enzolytics’ commitment to advancing innovative therapeutics. The company is actively exploring applications of this patent and preparing to initiate in-vitro studies under the Federal Drug Administration (FDA).[4]
Elimus Ltd.[edit]
Enzolytics, Inc. has entered into a 4-Year Collaboration Agreement with Elimus Ltd., a Bulgaria-based company, for the manufacturing, development, and marketing of nutraceutical products in North America. The agreement grants Enzolytics exclusive licensing rights to Elimus’ product catalog, including VIP Power, and allows the company to use Elimus’ manufacturing capacity as needed.[5]
Monoclonal Antibodies and Immune Therapeutic Proteins[edit]
Enzolytics, Inc. has entered into a three-year agreement with the Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences. The collaboration aims to combine Monoclonal Antibodies and Immune Therapeutic Proteins (ITP) for developing treatments for malignant antigens. Both parties will work on pharmacokinetics, pre-clinical, and clinical trials.[6]
Acquisition Strategy[edit]
Enzolytics, Inc. announced a capital restructuring plan in November, 2024 to support its acquisition and financing strategy. The company is negotiating multiple acquisitions and plans to implement a 1:1,000 reverse stock split of its common shares and convertible Preferred Series B, C, and F shares, pending approval. The restructuring is intended to facilitate transactions and adjust the company’s capital structure.[7]
- ↑ Yahoo Finance. ENZC Stock Profile. Accessed on 2/9/2025.
- ↑ Enzolytics.com. Anti HIV Therapeutics. Accessed on 2/9/2025. Archive link.
- ↑ Nasdaq. Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation. May 22, 2024.
- ↑ Yahoo. Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment. July 1, 2024.
- ↑ Yahoo Finance. Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd. July 29, 2024.
- ↑ Nasdaq. Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement. September 9, 2024.
- ↑ OTC Markets. ENZOLYTICS, INC. ANNOUNCES IMPLEMENTATION OF CAPITAL RESTRUCTURING PLAN AS PART OF ONGOING ACQUISITION STRATEGY OFFERS UPDATE ON SAGALIAM ACQUISITION CORP. November 6, 2024.
